


medicina

BUENOS AIRES VOL. 79 Supl. IV - 2019

80° Aniversario



medicina

BUENOS AIRES, VOL. 79 Supl. IV - 2019

COMITÉ DE REDACCIÓN

Pablo J. Azurmendi
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina
Damasia Becú Villalobos
Instituto de Biología y Medicina Experimental-CONICET, Buenos Aires, Argentina
José H. Casabé
Instituto de Cardiología y Cirugía Cardiovascular, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina
Eduardo L. De Vito
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina
Isabel Narvaiz Kantor
Organización Panamericana de la Salud (OPS/OMS) (ret.) Argentina
Basilio A. Kotsias
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina
Gustavo Kusminsky
Hospital Universitario Austral, Buenos Aires, Argentina
Isabel A. Lüthy
Instituto de Biología y Medicina Experimental (IBYME), Buenos Aires, Argentina

Aires, Argentina
Daniel A. Manigot
Hospital San Juan de Dios, Buenos Aires, Argentina
Jorge A. Manni
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina
Rodolfo S. Martin
Facultad de Ciencias Biomédicas y Hospital Universitario Austral, Buenos Aires, Argentina
Guillermo D. Mazzolini
Instituto de Investigaciones en Medicina Traslacional-CONICET, Hospital Universitario Austral, Buenos Aires, Argentina
Rodolfo C. Puche
Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Santa Fe, Argentina
Viviana Ritacco
Instituto Nacional de Enfermedades Infecciosas ANLIS-CONICET, Buenos Aires, Argentina
Guillermo B. Semeniuk
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

MIEMBROS EMÉRITOS

Héctor O. Alonso
Instituto Cardiovascular Rosario, Santa Fe, Argentina
Guillermo Jaim Etcheverry
Facultad de Medicina, UBA, Argentina
María Marta de Elizalde de Bracco
IMEX-CONICET-Academia Nacional de Medicina, Buenos Aires, Argentina

Argentina
Christiane Dosne Pasqualini
Academia Nacional de Medicina, Buenos Aires, Argentina

La Tapa (Ver pág. 4)
Atardecer en la tarde
Antonella Ricagni

MEDICINA (Buenos Aires) – Revista bimestral – ISSN 0025-7680 (Impresa) – ISSN 1669-9106 (En línea)

REVISTA BIMESTRAL
Registro de la Propiedad Intelectual N° 02683675
Personería Jurídica N° C-7497
Publicación de la Fundación Revista Medicina (Buenos Aires)
Propietario de la publicación: Fundación Revista Medicina
Queda hecho el depósito que establece la Ley 11723

Publicada con el apoyo del Ministerio de Ciencia, Tecnología e Innovación Productiva.
MEDICINA no tiene propósitos comerciales. El objeto de su creación ha sido propender al adelanto de la medicina argentina.
Los beneficios que pudieran obtenerse serán aplicados exclusivamente a este fin.
Aparece en MEDLINE (PubMed), ISI-THOMSON REUTERS (Journal Citation Report, Current Contents, Biological Abstracts, Biosis, Life Sciences), CABI (Global Health), ELSEVIER (Scopus, Embase, Excerpta Medica), SciELO, LATINDEX, BVS (Biblioteca Virtual en Salud), DOAJ, Google Scholar y Google Books.
Incluida en el Núcleo Básico de Revistas Científicas Argentinas del CONICET.

Directores Responsables:
Basilio A. Kotsias, Eduardo L. De Vito, Isabel Narvaiz Kantor, Guillermo B. Semeniuk
Secretaría de Redacción: Ethel Di Vita, Instituto de Investigaciones Médicas Alfredo Lanari, Combatientes de Malvinas 3150,
1427 Buenos Aires, Argentina
Tel. 5287-3827 Int. 73919 y 4523-6619
e-mail: revmedbuenosaires@gmail.com – http://www.medicinabuenosaires.com

Vol. 79, Supl. IV, Noviembre 2019

REUNIÓN ANUAL DE SOCIEDADES DE BIOCIENCIA 2019

**LXIV Reunión Anual de la
Sociedad Argentina de Investigación Clínica (SAIC)**

**LI Reunión Anual de la
Asociación Argentina de Farmacología Experimental (SAFE)**

**XXI Reunión Anual de la
Sociedad Argentina de Biología (SAB)**

**XXXI Reunión Anual de la
Sociedad Argentina de Protozoología (SAP)**

**IX Reunión Anual de la
Asociación Argentina de Nanomedicinas
(NANOMED-ar)**

**VI Reunión Científica Regional de la Asociación Argentina de Ciencia y
Tecnología de Animales de Laboratorio (AACyTAL)**

**con la participación de
The Histochemical Society**

**13 - 16 de noviembre de 2019
Hotel 13 de Julio - Mar del Plata**

EDITORES RESPONSABLES

**Dra. Mónica Costas
Dra. Gabriela Marino
Dr. Pablo Azurmendi**

arrest of hyperthermia-induced tonic freeze postures and occasional oral automatism (biting and chewing) and often body flexion. Rats were then placed on a cool surface, monitored for 5 min before being returned to their mothers. At PND37-39 rats were exposed to repeated pilocarpine subconvulsive doses (10 mg/kg every thirty minutes). Another group of animals (PND35) was deeply anesthetized, fixed and brains processed for immunohistochemistry. We observed that, contrary to the males, the females did not develop SE after four repeated doses of pilocarpine and histological analysis of their brains exhibited lower reactive gliosis compared to males. Our results suggest that HS exposure early in the postnatal brain development produce long-lasting effects in males, which could be related to their future susceptibility to develop epilepsy.

Supported by PICT 2015-1451; PICT 2017-2203; PIP CONICET and UBACYT grants.

0441 - NITRIC OXIDE AND APOPTOSIS DUE TO AFTER-EFFECTS OF ACUTE ETHANOL EXPOSURE IN BRAIN CORTEX

Analia KARADAYIAN (1) | **Analia CZERNICZYNIC**(1) | **Juanita BUSTAMANTE**(2) | **Silvia LORES ARNAIZ**(1)

INSTITUTO DE BIOQUIMICA Y MEDICINA MOLECULAR (IBIMOL-CONICET) (1); CENTRO DE ALTOS ESTUDIOS EN CIENCIAS HUMANAS Y DE LA SALUD, CAECIHS (UAI) (2)

Abstract/Resumen: Alcohol hangover (AH) is defined as a combination of mental and physical symptoms experienced the day after a single episode of heavy drinking, starting when blood alcohol concentration approaches to zero. We previously evidenced bioenergetics alterations and oxidative stress in brain cortex synaptosomes from AH mice. The aim of the present work was to study the after-effects of acute ethanol administration on nitric oxide (NO) metabolism, mitochondrial calcium uptake and induction of apoptosis. Mice received an i.p. injection of ethanol (3.8 g/kg body weight, AH group) or saline (control group) and were sacrificed 6 h afterwards. Synaptosomal NOS activity and total NO levels were determined, as well as the expression of nNOS, iNOS, PSD-95 and the NR2B-subunit of NMDA receptor. Mitochondrial calcium uptake, permeability transition (MPT) and the expression of apoptotic markers were analyzed in mitochondrial fractions. Results showed a 35-37 % decrease in NOS activity and total NO content in AH mice ($p < 0.05$), both in the absence and presence of glutamate and calcium. Protein expression of nNOS and PSD-95 were 19 and 15 % decreased, respectively ($p < 0.05$) while no changes were observed in iNOS protein expression. Furthermore, a 60 % decrease in NMDA receptor protein expression ($p < 0.01$) was found in AH synaptosomal membranes. Impairment of calcium handling and MPT induction were observed in AH mitochondria ($p < 0.05$) together with a 21 % increase and 18 % decrease in Bax and Bcl-2 protein expression ($p < 0.05$), respectively. Moreover, a 4-fold decrease in cytochrome c mitochondria/cytosol ratio was found due to AH ($p < 0.01$). In conclusion, alcohol after-effects include changes in NO synthesis probably related to the observed decrement in NMDAR and PSD-95 protein expression at synaptic membranes. Impairment of mitochondrial capacity to accumulate calcium due to mitochondrial dysfunction and oxidative stress can lead to cell death by the activation of apoptotic signalling pathways.

0452 - MODULATION OF METABOTROPIC AND IONOTROPIC FUNCTIONS OF THE NICOTINIC $\alpha 7$ RECEPTOR BY THE INTRACELLULAR DOMAIN

Juan Facundo CHRESTIA (1) | **Inés KÖLHER**(1) | **Ariana BRUZZONE**(2) | **Cecilia BOUZAT**(1) | **María Del Carmen ESANDI**(1)

INIBIBB-CONICET, DEPTO. BIOLOGÍA, BIOQUÍMICA Y FARMACIA-UNS (1); INIBIBB CONICET- INSTITUTO DE INVESTIGACIONES BIOQUÍMICAS DE BAHÍA BLANCA (2)

Abstract/Resumen: The $\alpha 7$ receptor is a nicotinic receptor present in the nervous system and in non-neuronal cells. It has been demonstrated that $\alpha 7$ not only mediates fast synaptic transmission in neurons, but also regulates inflammatory responses in immune cell, neurite growth and neuronal protection, as well as cancer cell proliferation. The concept of $\alpha 7$ as a dual metabotropic/ionotropic receptor is attracting increasing attention. A key role in this dual nature is played by the receptor intracellular domain (ICD), which contains sites for phosphorylation and intracellular signaling. To explore the relationship between metabotropic and ionotropic activities we expressed $\alpha 7$ in mammalian cells and performed single-channel recordings to determine the channel properties and western blot to determine signaling pathways triggered by $\alpha 7$ activation. Single-channel recordings of human $\alpha 7$ from cells exposed to inhibitors of Src family kinases showed increased open durations and frequency of opening events. The effects were recapitulated using a receptor carrying mutations of the two ICD tyrosine residues, thus indicating that phosphorylation modulates receptor ionotropic activity. Cells exposed to the specific $\alpha 7$ agonist, PNU-282987, showed an increase of ERK1/2 phosphorylation, which was abolished by exposure to a tyrosine kinase inhibitor. PNU-282987 was not able to trigger ERK phosphorylation neither from cells expressing the double mutant receptor lacking tyrosine residues nor from cells co-expressing $\alpha 7$ and the ICD domain. Finally, the exposure of cells co-expressing $\alpha 7$ and $\beta 2$ adrenergic receptors to nicotine ($\alpha 7$ agonist) and isoproterenol ($\beta 2$ agonist) decreased phosphorylation of CREB, a known effector of the $\beta 2$ adrenergic receptor. This study indicates that the phosphorylated state of $\alpha 7$ -ICD plays a role in the dual metabotropic/ionotropic receptor responses. It also opens doors for future studies exploring the role of the ICD as a modulator of the crosstalk between $\alpha 7$ and G-protein coupled receptors.

0752 - EXTRACELLULAR PROTEOLYSIS OF THE HORMONE GHRELIN GENERATES A SPECIFIC SUBSET OF GHRELIN-DERIVED PEPTIDES WITH DIFFERENTIAL BIOACTIVITIES

Antonela FITTIPALDI (1) | **Daniela LUFRANO**(1) | **Giμένα FERNANDEZ**(1) | **Daniel CASTROGIOVANNI**(1) | **Pablo N. DE FRANCESCO**(1) | **Leonard LUYT**(2) | **Sebastián TREJO**(3) | **Mario PERELLO**(1)

IMBICE (CICPBA-CONICET-UNLP) (1); DEPARTMENTS OF CHEMISTRY, ONCOLOGY, AND MEDICAL IMAGING, UNIVERSITY OF WESTERN ONTARIO (2); YPF TECNOLOGIA (3)

Abstract/Resumen: The stomach-derived hormone ghrelin is a peptide of 28 residues acylated with an octanoic acid at Ser3. The N-terminal sequence of ghrelin along with the octanoyl group are essential to act on the ghrelin receptor. Here, we tested the hypothesis that ghrelin can be extracellularly cleaved in order to generate ghrelin-derived peptides with differential bioactivities. Initially, we incubated ghrelin with plasma and then performed MALDI-TOF MS analysis. We found that ghrelin is mainly cleaved in the region extended from residue 11 to 16. Then, we incubated ghrelin with liver carcinoma HepG2 cells or with extracellular medium derived from these cells, and also found that ghrelin cleavage occurs in the same "hot cleavage region" of its sequence. Since ghrelin1-14 was derived from ghrelin proteolysis, we then tested the ability of this shorter version of ghrelin to act in the brain and stimulate appetite in mice. We found that ghrelin increases food intake (0.29 vs. 0.07 g in vehicle-injected mice, p -value 0.0008) while ghrelin1-14 failed to do it (0.005 g). Similarly, ghrelin increases the levels of the marker of neuronal activation c-Fos in the ARC (48.0 vs. 12.0 cells/side/section in vehicle-injected mice, p -value 0.0036) while ghrelin1-14 was unable to induce neuronal activation (16.1 cells/side/section). In addition, ghrelin1-14 failed to impair the orexigenic effect of full-length ghrelin. Thus, these data support the existence of a proteolytic extracellular mechanism that generates ghrelin-derived peptides with different bioactivity than ghrelin. Moreover, the liver may be involved in this mechanism